Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV

Glycosylated Receptor-Binding-Domain-Targeting Mucosal Vaccines Protect Against SARS-CoV-2 Omicron and MERS-CoV

Background. The pathogenic coronaviruses (CoVs) MERS-CoV and SARS-CoV-2, which are responsible for the MERS outbreak and the COVID-19 pandemic, respectively, continue to infect humans, with significant adverse outcomes. There is a continuing need to develop mucosal vaccines against these respiratory...

Full description

Saved in:
Bibliographic Details
Main Authors: Xiaoqing Guan, Abhishek K. Verma, Qian Liu, Melissa Palacios, Abby E. Odle, Stanley Perlman, Lanying Du
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Vaccines
Subjects:
pathogenic coronavirus
COVID-19
SARS-CoV-2
MERS-CoV
receptor-binding domain
mucosal immunity
Online Access:https://www.mdpi.com/2076-393X/13/3/293
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2076-393X/13/3/293

Similar Items